Rapid progress has been made in the design of heterobifunctional proteolysis targeting chimeras (PROTACs) and molecular glue degraders, targeting key lung cancer culprits, such as KRAS (84,98,99). The gene discussed is KRAS; the disease is lung carcinoma.